Fennec Pharmaceuticals
FENC
56 hedge funds and large institutions have $169M invested in Fennec Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 6 closing their positions.
31,400% more call options, than puts
Call options by funds: $630K | Put options by funds: $2K
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
57% more capital invested
Capital invested by funds: $108M → $169M (+$61.7M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2.76% more ownership
Funds ownership: 53.88% → 56.64% (+2.8%)
2% more funds holding
Funds holding: 55 → 56 (+1)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.77M |
| 2 |
Morgan Stanley
New York
|
+$926K |
| 3 |
BlackRock
New York
|
+$742K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$545K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$405K |
Top Sellers
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$2.88M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.33M |
| 3 |
DCM
DG Capital Management
New York
|
-$559K |
| 4 |
ACA
Apis Capital Advisors
New York
|
-$526K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$366K |
FENC Hedge Fund Activity: Q4 2023 in Review
56 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2023, worth a combined $169M — up 57% from $108M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FENC positions and 6 closed out — a net gain of 1 holder — while 23 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $8.77M. The largest seller was Solas Capital Management, cutting an estimated $2.88M.
- 56 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2023, up from 55 in Q3 2023.
- Funds reported $169M of Fennec Pharmaceuticals stock for Q4 2023, up 57% quarter-over-quarter.
- 7 funds opened new Fennec Pharmaceuticals positions in Q4 2023 and 6 closed out, a net change of +1 holder.
- The largest Fennec Pharmaceuticals buyer in Q4 2023 was Vanguard Group, an estimated $8.77M added.
- The largest Fennec Pharmaceuticals seller in Q4 2023 was Solas Capital Management, an estimated $2.88M sold.
Based on aggregated 13F filings for Q4 2023.